Detalhe da pesquisa
1.
Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain.
Eur J Clin Microbiol Infect Dis
; 38(6): 1105-1111, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30989419
2.
Economic impact of health resource optimisation in the approach to patients with hepatitis C. / Impacto económico de la optimización de los recursos asistenciales en el abordaje del paciente con hepatitis C.
Gastroenterol Hepatol
; 42 Suppl 1: 26-33, 2019 Sep.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-32560770
3.
[Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain]. / Análisis coste-utilidad de apixabán frente al ácido acetilsalicílico en la prevención del ictus en pacientes con fibrilación auricular no valvular en España.
Aten Primaria
; 48(6): 394-405, 2016.
Artigo
em Espanhol
| MEDLINE | ID: mdl-26832316
4.
Cost analysis of the adverse reactions of bipolar disorder treatment with aripiprazole and olanzapine in Spain.
Actas Esp Psiquiatr
; 42(5): 242-9, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25179096
5.
Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain.
J Comp Eff Res
; 12(11): e230115, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37712635
6.
Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain.
J Comp Eff Res
; 12(2): e220193, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36705064
7.
Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
Expert Rev Anti Infect Ther
; 21(1): 65-76, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399521
8.
Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain.
J Med Econ
; 26(1): 1145-1154, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37602646
9.
Clinical and economic benefit of 32 years of antiretroviral treatment for people living with HIV in Spain: Has it been an efficient intervention?
Enferm Infecc Microbiol Clin (Engl Ed)
; 40(10): 550-556, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34303633
10.
Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain.
Expert Rev Pharmacoecon Outcomes Res
; 21(2): 315-320, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32597317
11.
Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain.
Expert Rev Pharmacoecon Outcomes Res
; 21(2): 285-297, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32484365
12.
Clinical and economic benefit of 32 years of antiretroviral treatment for people living with HIV in Spain: Has it been an efficient intervention? / Beneficio clínico y económico de 32 años de tratamiento antirretroviral de personas que viven con VIH en España: ¿ha sido una intervención eficiente?
Enferm Infecc Microbiol Clin (Engl Ed)
; 2021 Jun 30.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-34217551
13.
Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain.
Expert Rev Pharmacoecon Outcomes Res
; 21(5): 1127-1133, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34047214
14.
Analysis of the Health and Budgetary Impact of Chondroitin Sulfate Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs.
Clinicoecon Outcomes Res
; 12: 505-514, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32982340
15.
[Analysis of costs and consequences related to the persistence of Mirabegron and antimuscarinic treatments and their impact on quality of life in patients with overactive bladder in Spain: Results of a probabilistic model.] / Análisis de costes y consecuencias relacionados con la persistencia del tratamiento con Mirabegrón y los fármacos antimuscarínicos y su impacto sobre la calidad de vida en los pacientes con vejiga hiperactiva en España: resultados de un modelo probabilístico.
Arch Esp Urol
; 73(6): 509-522, 2020 Jul.
Artigo
em Espanhol
| MEDLINE | ID: mdl-32633246
16.
Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain.
Expert Rev Pharmacoecon Outcomes Res
; 20(1): 105-114, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31055976
17.
Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain.
Rev Esp Cardiol (Engl Ed)
; 73(5): 361-367, 2020 May.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-31899185
18.
Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain.
Clinicoecon Outcomes Res
; 11: 465-475, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31413609
19.
[Cost-effectiveness model of a fixed dose combination of solifenacin and tamsulosin for the treatment of LUTS associated with BPH with inadequate response to monotherapy.] / Modelo de costeefectividad de la combinación a dosis fijas de solifenacina y tamsulosina en el tratamiento de los STUI asociados a HBP con respuesta inadecuada a la monoterapia.
Arch Esp Urol
; 71(7): 595-606, 2018 09.
Artigo
em Espanhol
| MEDLINE | ID: mdl-30198851
20.
[Cost effectiveness of Mirabegron and antimuscarinic drugs in patients with hiperactive bladder.] / Coste-efectividad de mirabegrón y los antimuscarínicos en pacientes con vejiga hiperactiva.
Arch Esp Urol
; 71(10): 809-824, 2018 Dec.
Artigo
em Espanhol
| MEDLINE | ID: mdl-30560796